Merck Advances Development Programs in Oncology Focusing on Novel Mechanisms and Pathways June 13, 2022
Modi-1 Ph 1/2 trial open for recruitment in patients with TNBC, ovarian cancer, head and neck cancer, and RCC April 12, 2022
First patient dosed with ADG106 + ADG116 combination in Ph 1b/2 trial in solid tumors January 28, 2022
First Patient Treated in Pivotal ENLIGHTED Study of Padeliporfin ImPACT in Low Grade Upper Tract Urothelial Cancer April 21, 2021
